retatrutide clinical trials dosing trial frequency Retatrutide Dosage Chart: Everything You Need to Know Phase III retatrutide study demonstrates

As with other GLP-1 agonists, retatrutide is likely to be unsuitable for those with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2

Regular check-ins with a healthcare provider are essential to monitor for any adverse effects

is approved for weight loss in adults and children ages 12 and over with obesity, and for adults with overweight plus at least one weight-related condition (such as type 2 diabetes or heart disease)

The authors of Do GLP-1 Medications Pay for Themselves? acknowledge support from Indiana Universitys Health Excellence Achieved through Learning Health Systems Research (HEALeR) Collaborative, and the National Institute for Healthcare Management Foundation.

Saudi Pharm

Int J Mol Med 41(5):29772985